secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001171843-26-003005
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics reports tovecimig Phase 2/3 BTC data with significant PFS benefit; BLA planned
--------------------------------------------------------------------------------

- Tovecimig + paclitaxel: ORR 17.1% vs 5.3% (p=0.031); PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001); OS crossover benefit.
- Company plans FDA meeting then BLA submission for tovecimig in second-line BTC by end of 2026.
- CTX-8371 cohort expansions in TNBC, NSCLC, HL initiated; dose-escalation data at ASCO 2026 poster.
- CTX-10726 Phase 1 study initiated; initial clinical data expected in Q4 2026.
- Cash and marketable securities $195M at Q1 2026; net loss $18.3M ($0.10/share); cash runway into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326003005/0001171843-26-003005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326003005/f8k_050426.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer